Celyad Announces the Appointment of Dr. Debasish Roychowdhury as Independent Director

MONT-SAINT-GUIBERT, Belgium--()--Regulatory News:

Celyad (Paris:CYAD) (Brussels:CYAD) (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced the appointment of Debasish F. Roychowdhury as new independent non-executive director.

Dr. Roychowdhury is a medical oncologist with over 15 years of comprehensive pharmaceutical industry experience and 14 years of patient care and academic research. In the pharmaceutical industry, Debasish held multiple positions of growing responsibility respectively at Eli Lilly, GSK and Sanofi, with direct therapeutic area experience mostly in oncology and hematology. Based in Boston, Massachusetts, Debasish is now using his extensive experience and global network to advise companies, organizations, and institutions in the biomedical field.

Dr. Roychowdhury’s appointment was effective 21 August 2015. Debasish will be replacing Jean-Marc Heynderickx who stepped down from the Board.

Michel Lussier, Chairman of the Board for Celyad, said: “The addition of Dr. Roychowdhury to the board is another key step to strengthening the strategic advice for our business plans and adds a depth of experience in oncology to help us realize the potential of the Natural Killer Receptor CAR-T portfolio we recently acquired. Also, a special and warm thanks to Jean-Marc Heynderickx who provided us with his solid support and advice for growth over the last three years.”

Dr. Christian Homsy, CEO of Celyad, added: “Our intention is to fully execute our strategic plan quickly focused on areas that we believe have the highest potential and value to patients. Dr. Roychowdhury will be another key partner to advise us on how best to deliver our engineered cell therapies to patients.”

To subscribe to Celyad’s newsletter, visit www.celyad.com
Follow us on Twitter @CelyadSA

About Celyad

Founded in 2007, and based in Belgium, Celyad is a leader in engineered cell therapy with clinical programs initially targeting indications in cardiology and oncology. Celyad is developing its lead cardiovascular disease product candidate, C-Cure®, for the treatment of ischemic heart failure, and has completed enrollment of a Phase III trial in Europe and Israel. In addition, the Company is developing a novel portfolio of CAR T-cell therapies that utilize human Natural Killer cell receptors for the treatment of numerous blood and solid cancers. Its lead oncology product candidate, NKG2D CAR T-cell, entered a Phase I clinical trial in April 2015.

Celyad’s ordinary shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CYAD and Celyad’s American Depositary Shares are listed on the NASDAQ Global Market under the ticker symbol CYAD.

To learn more about Celyad, please visit www.celyad.com

Forward looking statements

In addition to historical facts or statements of current condition, this press release contains forward-looking statements, including statements about the safety and efficacy of Celyad’s product candidates, the potential clinical and commercial potential of these product candidates and the adequacy of Celyad’s financial resources, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including risks associated with conducting clinical trials; the risk that DSMB’s determination not to discontinue the Phase III clinical trials for C-Cure® on the basis of non-futility is not a determination as to the likelihood of success and is not a guarantee that the trial will be successful; the risk that safety, bioactivity and efficacy demonstrated in earlier clinical or pre-clinical studies may not be replicated in subsequent studies; risk associated with the timely submission and approval of anticipated regulatory filings; the successful initiation and completion of clinical trials, including Phase III clinical trials for C-Cure® and Phase I clinical trial for NKG2D CAR T-cell; risks associated with the satisfaction of regulatory and other requirements; risks associated with the actions of regulatory bodies and other governmental authorities; risks associated with obtaining, maintaining and protecting intellectual property, our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; risks associated with competition from others developing products for similar uses; risks associated with our ability to manage operating expenses; and risks associated with our ability to obtain additional funding to support our business activities and establish and maintain strategic business alliances and business initiatives.

A further list and description of these risks, uncertainties and other risks can be found in the Company’s Securities and Exchange Commission filings and reports, including in the Company’s prospectus filed with the SEC on June 19, 2015 and future filings and reports by the Company. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. The Company expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

C3BS-CQR-1, C-Cure, NKG2D CAR T-cell, C-Cathez, OnCyte, Celyad, Cardio3 BioSciences and the Cardio3 BioSciences, Celyad, CHART-1, CHART-2 and OnCyte logos are signs internationally protected under applicable Intellectual Property Laws. Mayo Clinic holds equity in Celyad as a result of intellectual property licensed to the Company.

Contacts

For more information, please contact:
For Europe : Consilium Strategic Communications
Amber Fennell, Chris Gardner, Chris Welsh, and Laura Thornton
T: +44 (0)20 3709 5700
celyad@consilium-comms.com
or
For the U.S. : The Ruth Group
Lee Roth (Investors), and Kirsten Thomas (Media)
T: +1 646 536 7012 / 7014
celyad@theruthgroup.com
or
For France : NewCap
Pierre Laurent and Nicolas Mérigeau
T: + 33(0)1 44 71 94 94
celyad@newcap.fr
or
Celyad
Christian Homsy, CEO and Patrick Jeanmart, Chief Financial Officer
T: +32 (0)10 39 41 00
investors@celyad.com

Contacts

For more information, please contact:
For Europe : Consilium Strategic Communications
Amber Fennell, Chris Gardner, Chris Welsh, and Laura Thornton
T: +44 (0)20 3709 5700
celyad@consilium-comms.com
or
For the U.S. : The Ruth Group
Lee Roth (Investors), and Kirsten Thomas (Media)
T: +1 646 536 7012 / 7014
celyad@theruthgroup.com
or
For France : NewCap
Pierre Laurent and Nicolas Mérigeau
T: + 33(0)1 44 71 94 94
celyad@newcap.fr
or
Celyad
Christian Homsy, CEO and Patrick Jeanmart, Chief Financial Officer
T: +32 (0)10 39 41 00
investors@celyad.com